newsfilter
← Latest News
PR Newswire·

Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

HUDDINGE, Sweden, Aug. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and The Leukemia &